CN117551567B - Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof - Google Patents
Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117551567B CN117551567B CN202311260664.7A CN202311260664A CN117551567B CN 117551567 B CN117551567 B CN 117551567B CN 202311260664 A CN202311260664 A CN 202311260664A CN 117551567 B CN117551567 B CN 117551567B
- Authority
- CN
- China
- Prior art keywords
- fermentation
- hours
- lactobacillus
- increased
- cicc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000002124 endocrine Effects 0.000 title claims abstract description 17
- 210000001672 ovary Anatomy 0.000 title claims abstract description 13
- 210000001215 vagina Anatomy 0.000 title abstract description 11
- 206010054949 Metaplasia Diseases 0.000 title abstract description 5
- 230000015689 metaplastic ossification Effects 0.000 title abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 100
- 230000004151 fermentation Effects 0.000 claims abstract description 100
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims description 36
- 244000199866 Lactobacillus casei Species 0.000 claims description 24
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 24
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 24
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 24
- 229940017800 lactobacillus casei Drugs 0.000 claims description 24
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 18
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 18
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 14
- 239000001888 Peptone Substances 0.000 claims description 12
- 108010080698 Peptones Proteins 0.000 claims description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 12
- 235000015278 beef Nutrition 0.000 claims description 12
- 229940041514 candida albicans extract Drugs 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 12
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 12
- 235000019319 peptone Nutrition 0.000 claims description 12
- 239000001632 sodium acetate Substances 0.000 claims description 12
- 235000017281 sodium acetate Nutrition 0.000 claims description 12
- 239000012138 yeast extract Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 241001052560 Thallis Species 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 239000013530 defoamer Substances 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 5
- 235000018291 probiotics Nutrition 0.000 abstract description 5
- 230000000529 probiotic effect Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 41
- 241000700159 Rattus Species 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 10
- 102000009151 Luteinizing Hormone Human genes 0.000 description 9
- 108010073521 Luteinizing Hormone Proteins 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 229940040129 luteinizing hormone Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 210000004392 genitalia Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 230000009933 reproductive health Effects 0.000 description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010051873 Vaginal relaxation Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 238000012418 validation experiment Methods 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of microbial preparations, and particularly relates to a metaplasia product for regulating endocrine and maintaining vagina and ovary, and a preparation method and application thereof. The invention screens and obtains a lactobacillus paracasei (Lactobacillus paracasei) Nice-05, and based on the strain and combined with a multi-strain probiotic balanced fermentation product, a metazoan preparation product is finally successfully developed, and experiments prove that the metazoan preparation product can better adapt to intestinal environments so as to more effectively play a role of probiotics, and in particular, the metazoan preparation can effectively regulate endocrine and maintain vagina ovaries, so that the metazoan preparation has good practical application value.
Description
Technical Field
The invention belongs to the technical field of microbial preparations, and particularly relates to a metaplasia product for regulating endocrine and maintaining vagina and ovary, and a preparation method and application thereof.
Background
The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art.
For women, when the number of the vaginal microorganisms is large, the vagina is dry and the itching feeling is serious, the women can be greatly uncomfortable in daily life, and the women are damaged in physical and mental health. The diseases of the reproductive system such as colpitis, cervical erosion, breast diseases and the like can influence the health of female genitals, even lead to the problems of infertility and the like. The unhealthy ovaries also cause a series of problems with endocrine dyscrasia, which can cause abnormal functions of the body's organs such as metabolism, differentiation, growth and development.
Reproductive health has been defined as the core science of human life and is listed in the world health organization "compendium of action", and women have a more intimate relationship between their genitals and other organs within the body due to their special physiology, and are susceptible to external factors such as contamination and infection, so that women are particularly required to pay attention to the health of their genitals. Female genital health plays a vital role in the physical, reproductive, psychological and endocrine health of females. In order to maintain the health of female genitals, women should pay attention to personal hygiene, and regularly perform gynecological examination to maintain a pleasant and balanced nutrition level. In addition, for some genital diseases, such as endometritis, breast abnormality, cervical diseases and the like, the early detection and treatment are helpful for keeping female genitalia healthy and well preventing the female genitalia from causing unnecessary influence.
The pharmaceutical preparations for female reproductive health treatment in the market at present mainly comprise oral agents, injections, gel agents, vaginal rings and the like. The vaginal gel and the vaginal ring are inconvenient to use for a long time because of the privacy medication, and can cause side effects such as vaginal dryness and the like. Most women are often photophobized to the mouth for reproductive health problems, and fear goes to inquiry by themselves, so the trouble of gradually improving the reproductive health problems through oral administration of a regulator is a better solution. In combination with the analysis, the advantage of the oral administration of the traditional Chinese medicine composition for promoting the primordial qi to maintain the genitalia is obviously greater than that of other treatment methods.
Disclosure of Invention
Based on the defects of the prior art, the invention provides a metagen product for regulating endocrine and maintaining vagina and ovary, and a preparation method and application thereof, and animal and human body experiments prove that the metagen preparation prepared by the invention has the effects of regulating endocrine and maintaining vagina and ovary, thereby effectively solving the problems of poor treatment effect, poor patient compliance and the like of the existing treatment method. Based on the above results, the present invention has been completed.
In order to achieve the technical purpose, the invention relates to the following technical scheme:
In one aspect of the invention, lactobacillus paracasei (Lactobacillus paracasei) Nice-05 is provided and is preserved in China center for type culture collection (address: university of Wuhan mountain and Wuhan of Wuhan, hubei province), with a preservation date of 2023 and 30 months and a biological preservation number of CCTCC NO: m20231154.
In a second aspect of the invention, a metagen preparation is provided, which comprises at least inactivated Lactobacillus paracasei Nice-05 and its fermentation metabolites.
In a third aspect of the present invention, there is provided a method for preparing the metapreparation, the method specifically comprising:
S1, strain activation: streaking the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CCTCC 22213 and Lactobacillus casei CICC 23184 into an activation culture medium to obtain pure strain;
s2, preparing primary seed liquid: respectively picking single colonies of Lactobacillus paracasei Lactobacillus PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 prepared in the step S1, placing the single colonies in a first culture solution at 28-30 ℃ for static culture for 12-14 hours to obtain a first-stage seed solution;
s3, preparing a secondary seed solution: inoculating the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into the second culture solution according to the ratio of the number of the thalli of 1:1:1, and standing at 28-35deg.C (preferably 30deg.C) for 12-14 hours to obtain the secondary seed solution.
S4, primary fermentation of the compound bacteria: inoculating the above compound bacteria into a fermenter containing sterilized culture solution according to an inoculum size of 2-5% (preferably 3%) at 28deg.C, 40-50r/min (preferably 40 r/min), and culturing for 3-4 hr;
S5, a multi-strain equilibrium fermentation stage I: after 3-4 hours, the stirring rotation speed is increased to 60-80r/min (preferably 70 r/min), the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2-3 hours;
s6, a multi-strain balanced fermentation stage II: after 5-7 hours, stirring speed and temperature are kept unchanged, tank pressure is increased to 0.1MPa, pH is regulated to 6.5 by ammonia water, and fermentation is carried out for 4-5 hours;
S7, multi-strain balanced fermentation stage III: after 9-12 hours, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours;
s8, a multi-strain balanced fermentation stage IV: after 11-14 hours, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerol with a volume of 0.1-0.2% (preferably 0.1%) of the fermentation broth is added into the fermentation tank, and the temperature is increased to 85 ℃ and maintained for 30min.
In a fourth aspect of the invention, the application of the metazoan preparation in preparing products for regulating endocrine and maintaining vagina and ovary is provided.
The product for regulating endocrine and maintaining vagina and ovary can be food or medicine.
The beneficial technical effects of one or more of the technical schemes are as follows:
The intestinal microorganisms of human bodies are various in variety, and the intestinal microorganisms maintain the stability of the internal environment of the human bodies through the synergistic effect of the intestinal microorganisms and play a very important role in digestion, absorption, immunity, metabolism and the like. The greater the number of strains involved in probiotics and their metabolites, the more advantageous the efficacy will be against the complexity of the intestinal microbial composition. The multi-strain balanced fermentation is a technology for fermenting by utilizing the combined action of a plurality of beneficial bacteria, and a plurality of different microorganisms participate in the fermentation, so that different metabolic pathways and enzyme systems of different strains can be utilized to generate different types and amounts of metabolites, thereby playing various functions and having more comprehensive effects. Meanwhile, the interaction among different strains can promote the generation and release of each metabolite and play a synergistic effect. The multi-strain probiotic balanced fermentation product can better adapt to the intestinal environment, so that the probiotic effect can be effectively exerted, and the multi-strain probiotic balanced fermentation product has good practical application value.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention.
FIG. 1 shows serum testosterone levels in rats in an efficacy validation experiment of the present invention;
FIG. 2 shows serum luteinizing hormone levels in rats in the efficacy verification experiments of the present invention;
FIG. 3 shows the serum follicle stimulating hormone levels of rats in the efficacy validation experiment of the present invention;
FIG. 4 shows the ratio of serum luteinizing hormone to follicle-stimulating hormone of rats in the experiment for verifying the effect of the present invention;
FIG. 5 is a statistical chart showing improvement of the private protection before and after taking in the effect verification experiment of the invention.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments in accordance with the present application. As used herein, the singular is also intended to include the plural unless the context clearly indicates otherwise, and furthermore, it is to be understood that the terms "comprises" and/or "comprising" when used in this specification are taken to specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof.
In one embodiment of the invention, a lactobacillus paracasei (Lactobacillus paracasei) Nice-05 is provided and preserved in China center for type culture collection (address: university of Wuchang mountain and Lopa nationality in Wuhan, hubei province), with a preservation date of 2023, 30 days, and a biological preservation number of CCTCC NO: m20231154.
In yet another embodiment of the present invention, there is provided a metagen preparation comprising at least inactivated lactobacillus paracasei Nice-05 and its fermentation metabolites;
Further, the metagen preparation comprises inactivated lactobacillus paracasei Nice-05, inactivated lactobacillus plantarum cctccc 22213 and inactivated lactobacillus casei cic 23184 and fermentation metabolites thereof.
Accordingly, in still another embodiment of the present invention, there is provided a method for preparing the above-mentioned metapreparation, the method specifically comprising:
S1, strain activation: streaking the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CCTCC 22213 and Lactobacillus casei CICC 23184 into an activation culture medium to obtain pure strain;
wherein the composition of the activation medium is as follows: 0.2% of yeast peptone, 0.5% of beef extract, 0.2% of yeast extract powder, 0.1% of sodium acetate, 0.1% of potassium dihydrogen phosphate and 0.15-0.2% of agar powder, and regulating the pH value to 6.5.
S2, preparing primary seed liquid: respectively picking single colonies of Lactobacillus paracasei Lactobacillus PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 prepared in the step S1, placing the single colonies in a first culture solution at 28-30 ℃ for static culture for 12-14 hours to obtain a first-stage seed solution;
The first culture solution comprises the following components: yeast peptone 0.2%, beef extract 0.5%, yeast extract 0.2%, sodium acetate 0.2%, potassium dihydrogen phosphate 0.2%, and pH adjusted to 6.5.
S3, preparing a secondary seed solution: inoculating the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into the second culture solution according to the ratio of the number of the thalli of 1:1:1, and standing at 28-35deg.C (preferably 30deg.C) for 12-14 hours to obtain the secondary seed solution.
The composition of the second culture solution is as follows: 2% of yeast peptone, 0.5% of beef extract, 0.5% of yeast extract powder, 3% of fructo-oligosaccharide, 1% of yeast powder, 0.2% of tween-80, 2% of yam starch, 0.2% of sodium acetate, 0.2% of potassium dihydrogen phosphate and pH 6.5.
S4, primary fermentation of the compound bacteria: inoculating the above compound bacteria into a fermenter containing sterilized culture solution according to an inoculum size of 2-5% (preferably 3%) at 28deg.C, 40-50r/min (preferably 40 r/min), and culturing for 3-4 hr;
The composition of the culture solution is as follows: 2% of yeast peptone, 0.5% of beef extract, 0.5% of yeast extract powder, 3% of fructo-oligosaccharide, 1% of yeast powder, 0.2% of tween-80, 2% of yam starch, 0.2% of sodium acetate, 0.2% of monopotassium phosphate, 3% of isomaltooligosaccharide, 5% of fructooligosaccharide, 3% of water-soluble starch, 0.5% of tyrosine, 0.2% of polyether defoamer and 6.5 of pH.
S5, a multi-strain equilibrium fermentation stage I: after 3-4 hours, the stirring rotation speed is increased to 60-80r/min (preferably 70 r/min), the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2-3 hours;
s6, a multi-strain balanced fermentation stage II: after 5-7 hours, stirring speed and temperature are kept unchanged, tank pressure is increased to 0.1MPa, pH is regulated to 6.5 by ammonia water, and fermentation is carried out for 4-5 hours;
S7, multi-strain balanced fermentation stage III: after 9-12 hours, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours;
s8, a multi-strain balanced fermentation stage IV: after 11-14 hours, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerol with a volume of 0.1-0.2% (preferably 0.1%) of the fermentation broth is added into the fermentation tank, and the temperature is increased to 85 ℃ and maintained for 30min.
In yet another embodiment of the present invention, the preparation method further includes a step of spray-drying the fermentation broth prepared in step S8.
In a further embodiment of the invention, the use of the metazoan preparation described above for the preparation of products for regulating endocrine and maintaining vaginal ovaries is provided.
The product for regulating endocrine and maintaining vagina and ovary can be food or medicine.
Specifically, the product can effectively reduce the serum testosterone and luteinizing hormone content of rats in a PCOS model.
The term "food product" as used in the present invention may be in any form that can be consumed, including both normal foods and special foods, including health foods and special medical use formulas; whereas a general food is a food suitable for all people, as opposed to a special food.
The medicine of the present invention may also contain common carrier, excipient, diluent, etc. Further, the composition can be formulated into various dosage forms such as powders, granules, suspensions, emulsions, syrups, sprays, etc., for oral administration, external use, suppositories, and sterile injectable solutions by a usual method.
The invention is further illustrated by the following examples, which are not to be construed as limiting the invention. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Wherein, lactobacillus plantarum CICC 22213 and lactobacillus casei CICC 23184 are purchased in China center for type culture Collection of microorganisms.
Example 1
Streaking the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into an activation culture medium (yeast peptone 0.2%, beef extract 0.5%, yeast extract 0.2%, sodium acetate 0.1%, potassium dihydrogen phosphate 0.1%, agar powder 0.15% and adjusting pH to 6.5) to obtain pure strain; respectively picking Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 single colony prepared in the step S1, placing the single colony in a first culture solution (yeast peptone 0.2%, beef extract 0.5%, yeast extract 0.2%, sodium acetate 0.2%, potassium dihydrogen phosphate 0.2% and pH value adjusted to 6.5) at 30 ℃ for static culture for 12 hours to obtain a first-stage seed solution; inoculating Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into a second culture solution (yeast peptone 2%, beef extract 0.5%, yeast extract 0.5%, fructo-oligosaccharide 3%, yeast powder 1%, tween-80.2%, yam starch 2%, sodium acetate 0.2%, potassium dihydrogen phosphate 0.2% and pH 6.5) according to the ratio of 1:1:1, and standing at 30deg.C for 12 hr to obtain a second seed solution; inoculating the composite bacteria into a fermentation tank containing sterilized culture solution (yeast peptone 2%, beef extract 0.5%, yeast extract 0.5%, fructo-oligosaccharide 3%, yeast powder 1%, tween-80.2%, yam starch 2%, sodium acetate 0.2%, potassium dihydrogen phosphate 0.2%, isomaltooligosaccharide 3%, fructooligosaccharide 5%, water-soluble starch 3%, tyrosine 0.5%, polyether defoamer 0.2%, and pH 6.5) according to an inoculation amount of 3%, and culturing at 28deg.C for 4 hr/min at 40 r/min; then the stirring rotation speed is increased to 70r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2 hours; then stirring speed and temperature are kept unchanged, tank pressure is increased to 0.1MPa, pH is regulated to 6.5 by ammonia water, and fermentation is carried out for 4 hours; then the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours; then, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerin with the volume of 0.1% of the fermentation liquor is added into a fermentation tank, the temperature is increased to 85 ℃ and kept for 30min, and powder is obtained after spray drying.
Example 2
Streaking the Lactobacillus paracasei PARACASEI NICE-05 into an activation culture medium to obtain a pure strain; picking a single bacterial colony of Lactobacillus paracasei PARACASEI NICE-05 prepared in the step S1, placing the single bacterial colony in a first culture solution at 30 ℃ for static culture for 12 hours to obtain a first-stage seed solution; inoculating the lactobacillus paracasei into a fermentation tank containing sterilized culture solution according to the inoculation amount of 3%, and culturing for 4 hours at 28 ℃ and 40 r/min; then, the stirring rotation speed is increased to 70r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2 hours; then stirring speed and temperature are kept unchanged, tank pressure is increased to 0.1MPa, pH is regulated to 6.5 by ammonia water, and fermentation is carried out for 4 hours; then the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours; then, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerin with the volume of 0.1% of the fermentation liquor is added into a fermentation tank, the temperature is increased to 85 ℃ and kept for 30min, and powder is obtained after spray drying.
Example 3
Streaking the Lactobacillus paracasei PARACASEI NICE-05 and Lactobacillus plantarum CICC 22213 into an activation culture medium to obtain a pure strain; respectively picking single bacterial colonies of Lactobacillus paracasei Lactobacillus PARACASEI NICE-05 and Lactobacillus plantarum CICC 22213 prepared in the step S1, placing the single bacterial colonies in a first culture solution at 30 ℃ for static culture for 12 hours to obtain a first-stage seed solution; inoculating the Lactobacillus paracasei PARACASEI NICE-05 and Lactobacillus plantarum CICC 22213 into a second culture solution according to the ratio of the number of the thalli being 1:1, and standing and culturing at 30 ℃ for 12 hours to obtain a secondary seed solution; inoculating the composite bacteria into a fermentation tank containing sterilized culture solution according to the inoculation amount of 3%, and culturing for 4 hours at 28 ℃ and 40 r/min; then, the stirring rotation speed is increased to 70r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2 hours; then, the stirring speed and the temperature are kept unchanged, the tank pressure is increased to 0.1MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 4 hours; then, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours; then, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerin with the volume of 0.1% of the fermentation liquor is added into a fermentation tank, the temperature is increased to 85 ℃ and kept for 30min, and powder is obtained after spray drying.
Example 4
Streaking the Lactobacillus paracasei PARACASEI NICE-05 and Lactobacillus casei CICC 23184 into an activation culture medium to obtain a pure strain; respectively picking single colonies of Lactobacillus paracasei Lactobacillus PARACASEI NICE-05 and Lactobacillus casei CICC 23184 prepared in the step S1, placing the single colonies in a first culture solution at 30 ℃ for static culture for 12 hours to obtain a first-stage seed solution; inoculating the Lactobacillus paracasei PARACASEI NICE-05 and Lactobacillus casei CICC 23184 into a second culture solution according to the ratio of 1:1 of the number of the bacteria, and standing at 30deg.C for 12 hours to obtain a secondary seed solution; inoculating the composite bacteria into a fermentation tank containing sterilized culture solution according to the inoculation amount of 3%, and culturing for 4 hours at 28 ℃ and 40 r/min; then, the stirring rotation speed is increased to 70r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2 hours; then, the stirring speed and the temperature are kept unchanged, the tank pressure is increased to 0.1MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 4 hours; then, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours; then, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerin with the volume of 0.1% of the fermentation liquor is added into a fermentation tank, the temperature is increased to 85 ℃ and kept for 30min, and powder is obtained after spray drying.
Example 5
Streaking the lactobacillus plantarum CICC 22213 and lactobacillus casei CICC 23184 into an activation culture medium to obtain a pure strain; respectively picking single colonies of the lactobacillus plantarum CICC 22213 and the lactobacillus casei CICC 23184 prepared in the step S1, placing the single colonies in a first culture solution at 30 ℃ for static culture for 12 hours to obtain a first-stage seed solution; inoculating the lactobacillus plantarum CICC 22213 and lactobacillus casei CICC 23184 into a second culture solution according to the ratio of the number of thalli to 1:1, and standing and culturing at 30 ℃ for 12 hours to obtain a secondary seed solution; inoculating the composite bacteria into a fermentation tank containing sterilized culture solution according to the inoculation amount of 3%, and culturing for 4 hours at 28 ℃ and 40 r/min; then, the stirring rotation speed is increased to 70r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2 hours; then, the stirring speed and the temperature are kept unchanged, the tank pressure is increased to 0.1MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 4 hours; then, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40r/min, the tank pressure is kept at 0.15MPa, the pH is kept natural, and the fermentation is carried out for 2 hours; then, the stirring speed is unchanged, the temperature is increased to 45 ℃, glycerin with the volume of 0.1% of the fermentation liquor is added into a fermentation tank, the temperature is increased to 85 ℃ and kept for 30min, and powder is obtained after spray drying.
Effect verification
1. Rat experiment
50 Healthy male SPF-grade SD rats with 21 days of age and uniform weight are selected, 10 normal rats are randomly separated, and the remaining 40 rats are fed with high-fat animal feed to establish a high-fat induction type PCOS rat model. The 40 PCOS rats were randomly grouped, 10 per group, model group, example 1 group, example 2 group, example 3 group, example 4 group and example 5 group, respectively. Normal and model group rats were fed normal animal feed, and each metagroup rat was fed feed containing 50mg/kg/d metage, for 8 weeks; rats in each group were fasted for 12 hours after 8 weeks, and peritoneal anesthesia was performed with 10% chloral hydrate solution, and blood was taken from the inferior vena cava. Placing the extracted serum sample for 2h, placing into a centrifuge with the speed of 3 000r/min, centrifuging for 15min, and taking the upper serum. Serum samples taken from the inferior vena cava were tested using ELISA kit, and the level of FSH, LH, TP in the serum of each group of rats was measured to calculate the LH/FSH ratio.
As a result, the serum Testosterone (TP) and Luteinizing Hormone (LH) contents of PCOS rats are remarkably increased, and the TP, LH and LH/FSH contents are remarkably reduced after taking metaplasia.
2. Endocrine regulating small-scale crowd experiment
20 Women aged 40-60 years voluntarily conducted the test and were able to complete questionnaires and recordings, and those suffering from endocrine problems were included in the test group. 600mg of metazoan (product prepared in example 1) is orally administered daily on an empty stomach in the morning for 4 weeks. Questionnaires were conducted before and after administration. The original eating habit is not changed during drinking, and the food is normally eaten.
98% Of the people before taking the medicine show trouble in aspects of endocrine, gynecological inflammation and the like, wherein the trouble comprises irregular menstrual cycle, vaginal itching, inflammation, vaginal dryness, vaginal relaxation, vaginal secretion increase, serious peculiar smell and the like; after the metazoan is taken, 100% of people show remarkable improvement, including menstrual cycle regulation, vaginal relaxation, vaginal dryness, vaginal secretion, no peculiar smell, vaginal itching, inflammation and the like.
Finally, it should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and the present invention is not limited to the above-mentioned embodiments, but may be modified or substituted for some of them by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention. While the foregoing describes the embodiments of the present invention, it should be understood that the present invention is not limited to the embodiments, and that various modifications and changes can be made by those skilled in the art without any inventive effort.
Claims (11)
1. Lactobacillus paracasei (Lactobacillus paracasei) Nice-05 is preserved in China center for type culture Collection, the preservation date is 2023 and 06 months 30, and the biological preservation number is CCTCC NO: m20231154.
2. A metagen preparation, characterized in that it contains at least inactivated lactobacillus paracasei Nice-05 according to claim 1 and its fermentation metabolites.
3. A metapreparation according to claim 2, wherein the metapreparation comprises inactivated lactobacillus paracasei Nice-05, inactivated lactobacillus plantarum CICC 22213 and inactivated lactobacillus casei CICC 23184 and fermentation metabolites thereof.
4.A method of preparing a metapreparation according to claim 2, wherein the method of preparing comprises:
S1, strain activation: streaking the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into an activation culture medium to obtain pure strain;
S2, preparing primary seed liquid: respectively picking single bacterial colonies of lactobacillus paracasei Lactobacillus paracaseiNice-05, lactobacillus plantarum CICC 22213 and lactobacillus casei CICC 23184 prepared in the step S1, placing the single bacterial colonies in a first culture solution at 28-30 ℃ for static culture for 12-14 hours to obtain primary seed solution;
S3, preparing a secondary seed solution: inoculating the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into a second culture solution according to the ratio of the number of the thalli of 1:1:1, and standing and culturing at 28-35 ℃ for 12-14 hours to obtain a secondary seed solution;
S4, primary fermentation of the compound bacteria: inoculating the composite bacteria into a fermentation tank containing sterilized culture solution according to the inoculum size of 2-5%, and culturing for 3-4 hours at 28 ℃ and 40-50 r/min;
S5, a multi-strain equilibrium fermentation stage I: after 3-4 hours, the stirring rotation speed is increased to 60-80 r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08 MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2-3 hours;
S6, a multi-strain balanced fermentation stage II: after 5-7 hours, the stirring speed and temperature are kept unchanged, the tank pressure is increased to 0.1 MPa, the pH value is regulated to 6.5 by ammonia water, and the fermentation is carried out for 4-5 hours;
s7, multi-strain balanced fermentation stage III: after 9-12 hours, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40 r/min, the tank pressure is kept at 0.15 MPa, the pH is kept natural, and the fermentation is carried out for 2 hours;
s8, a multi-strain balanced fermentation stage IV: after 11-14 hours, stirring speed is unchanged, temperature is increased to 45 ℃, glycerin with the volume of 0.1-0.2% of the fermentation liquor is added into the fermentation tank, and temperature is increased to 85 ℃ and kept at 30 min.
5. The method of preparing the metapreparation of claim 4, wherein the method of preparing comprises:
S1, strain activation: streaking the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into an activation culture medium to obtain pure strain;
S2, preparing primary seed liquid: respectively picking single bacterial colonies of lactobacillus paracasei Lactobacillus paracaseiNice-05, lactobacillus plantarum CICC 22213 and lactobacillus casei CICC 23184 prepared in the step S1, placing the single bacterial colonies in a first culture solution at 28-30 ℃ for static culture for 12-14 hours to obtain primary seed solution;
S3, preparing a secondary seed solution: inoculating the Lactobacillus paracasei PARACASEI NICE-05, lactobacillus plantarum CICC 22213 and Lactobacillus casei CICC 23184 into a second culture solution according to the ratio of the number of the thalli of 1:1:1, and standing at 30 ℃ for 12-14 hours to obtain a secondary seed solution;
s4, primary fermentation of the compound bacteria: inoculating the composite bacteria into a fermentation tank containing sterilized culture solution according to an inoculum size of 3%, and culturing for 3-4 hours at 28 ℃ and 40 r/min;
S5, a multi-strain equilibrium fermentation stage I: after 3-4 hours, the stirring rotation speed is increased to 70 r/min, the fermentation temperature is increased to 30 ℃, the tank pressure is kept at 0.08 MPa, the pH is regulated to 6.5 by ammonia water, and the fermentation is carried out for 2-3 hours;
S6, a multi-strain balanced fermentation stage II: after 5-7 hours, the stirring speed and temperature are kept unchanged, the tank pressure is increased to 0.1 MPa, the pH value is regulated to 6.5 by ammonia water, and the fermentation is carried out for 4-5 hours;
S7, multi-strain balanced fermentation stage III: after 9-12 hours, the fermentation temperature is increased to 35 ℃, the stirring rotation speed is reduced to 40 r/min, the tank pressure is kept at 0.15 MPa, the pH is kept natural, and the fermentation is carried out for 2 hours;
S8, a multi-strain balanced fermentation stage IV: after 11-14 hours, the stirring speed was unchanged, the temperature was increased to 45 ℃, glycerol was added to the fermenter in an amount of 0.1% by volume of the broth, and the temperature was increased to 85 ℃ to maintain 30 min.
6. The method of claim 4, wherein the composition of the activation medium is as follows: 0.2% of yeast peptone, 0.5% of beef extract, 0.2% of yeast extract powder, 0.1% of sodium acetate, 0.1% of potassium dihydrogen phosphate and 0.15-0.2% of agar powder, and regulating the pH value to 6.5.
7. The method of claim 4, wherein the first culture medium comprises the following composition: yeast peptone 0.2%, beef extract 0.5%, yeast extract 0.2%, sodium acetate 0.2%, potassium dihydrogen phosphate 0.2%, and pH adjusted to 6.5.
8. The method of claim 4, wherein the second culture medium comprises the following composition: 2% of yeast peptone, 0.5% of beef extract, 0.5% of yeast extract powder, 3% of fructo-oligosaccharide, 1% of yeast powder, 0.2% of tween-80, 2% of yam starch, 0.2% of sodium acetate, 0.2% of potassium dihydrogen phosphate and pH 6.5.
9. The method of claim 4, wherein the composition of the culture solution in step S4 is as follows: 2% of yeast peptone, 0.5% of beef extract, 0.5% of yeast extract powder, 3% of fructo-oligosaccharide, 1% of yeast powder, 0.2% of tween-80, 2% of yam starch, 0.2% of sodium acetate, 0.2% of monopotassium phosphate, 3% of isomaltooligosaccharide, 5% of fructooligosaccharide, 3% of water-soluble starch, 0.5% of tyrosine, 0.2% of polyether defoamer and 6.5 of pH.
10. The process according to any one of claims 4 to 9, further comprising a step of spray-drying the fermentation broth obtained in step S8.
11. Use of lactobacillus paracasei Nice-05 according to claim 1, a metagen preparation according to claim 2 for preparing products for regulating endocrine and maintaining vaginal ovaries.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311260664.7A CN117551567B (en) | 2023-09-27 | 2023-09-27 | Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311260664.7A CN117551567B (en) | 2023-09-27 | 2023-09-27 | Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117551567A CN117551567A (en) | 2024-02-13 |
| CN117551567B true CN117551567B (en) | 2024-06-04 |
Family
ID=89813537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311260664.7A Active CN117551567B (en) | 2023-09-27 | 2023-09-27 | Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117551567B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040101335A (en) * | 2002-03-21 | 2004-12-02 | 비포단 에이/에스 | Lactobacillus strains |
| WO2014021733A1 (en) * | 2012-08-01 | 2014-02-06 | Abramov Vyacheslav Mihaylovich | Strains and consortium of probiotic strains of lactobacillus crispatus 2029, lactobacillus gasseri 2016 and lactobacillus plantarum 2025 for producing a bacterial preparation and starter culture |
| CN104431355A (en) * | 2014-11-24 | 2015-03-25 | 青岛科技大学 | Method for preparing lactic acid bacterium granule capsule |
| CN104894021A (en) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | Lactobacillus paracasei strain and application thereof |
| CN106957811A (en) * | 2017-05-22 | 2017-07-18 | 泰安大凡神农制药有限公司 | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation |
| CN110693007A (en) * | 2019-10-25 | 2020-01-17 | 李玉保 | Probiotics compound nutrient for inhibiting gynecological inflammation and promoting cell metabolism and preparation method thereof |
| WO2023021353A1 (en) * | 2021-08-17 | 2023-02-23 | Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) | Commensal bacteria promote endocrine-resistance in prostate cancer via androgen biosynthesis |
| CN116173112A (en) * | 2023-02-28 | 2023-05-30 | 江苏新法奥医疗科技有限公司 | Traditional Chinese medicine formula probiotic composition, preparation method and application thereof in improving male sexual function |
| CN116590184A (en) * | 2023-04-28 | 2023-08-15 | 山东康祐生物科技有限公司 | Metaplasia product for improving immunity and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116536201B (en) * | 2023-05-06 | 2023-09-22 | 山东奈思健康科技有限责任公司 | Metaplasia preparation for repairing pelvic floor muscles and preparation method and application thereof |
-
2023
- 2023-09-27 CN CN202311260664.7A patent/CN117551567B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040101335A (en) * | 2002-03-21 | 2004-12-02 | 비포단 에이/에스 | Lactobacillus strains |
| WO2014021733A1 (en) * | 2012-08-01 | 2014-02-06 | Abramov Vyacheslav Mihaylovich | Strains and consortium of probiotic strains of lactobacillus crispatus 2029, lactobacillus gasseri 2016 and lactobacillus plantarum 2025 for producing a bacterial preparation and starter culture |
| CN104431355A (en) * | 2014-11-24 | 2015-03-25 | 青岛科技大学 | Method for preparing lactic acid bacterium granule capsule |
| CN104894021A (en) * | 2015-06-03 | 2015-09-09 | 宜兰食品工业股份有限公司 | Lactobacillus paracasei strain and application thereof |
| CN106957811A (en) * | 2017-05-22 | 2017-07-18 | 泰安大凡神农制药有限公司 | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation |
| CN110693007A (en) * | 2019-10-25 | 2020-01-17 | 李玉保 | Probiotics compound nutrient for inhibiting gynecological inflammation and promoting cell metabolism and preparation method thereof |
| WO2023021353A1 (en) * | 2021-08-17 | 2023-02-23 | Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) | Commensal bacteria promote endocrine-resistance in prostate cancer via androgen biosynthesis |
| CN116173112A (en) * | 2023-02-28 | 2023-05-30 | 江苏新法奥医疗科技有限公司 | Traditional Chinese medicine formula probiotic composition, preparation method and application thereof in improving male sexual function |
| CN116590184A (en) * | 2023-04-28 | 2023-08-15 | 山东康祐生物科技有限公司 | Metaplasia product for improving immunity and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 乳酸菌在疾病防治和人体保健中的应用研究进展;唐京等;《微生物学杂志》;20170815(4);104-113 * |
| 植物乳杆菌的功能性及工业化应用研究进展;冯丽莉等;中国乳品工业;20180325(3);36-38、65 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117551567A (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105054040B (en) | A kind of composition of probiotics fermention ginseng and its preparation method and application | |
| JP5525622B2 (en) | Compound microorganism preparation for the treatment of diabetes, its production method and use | |
| CN104770575B (en) | A kind of Radix Astragali probiotics and its preparation method and application | |
| CN110106119B (en) | Lactobacillus rhamnosus M9 separated from breast milk and application thereof | |
| CN108244432A (en) | A kind of fermentation Cordyceps militaris probiotic beverage and preparation method thereof | |
| CN113577128A (en) | Astragalus membranaceus fermentation liquor as well as preparation method and application thereof | |
| CN109123141A (en) | A kind of application of preparation method of fermented tcm dreg fodder and products thereof, product | |
| CN114921389A (en) | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof | |
| CN103446552A (en) | Fermented composition for preventing and treating digestive system diseases | |
| CN109364114A (en) | A kind of fermented tcm and preparation method thereof improving cattle and sheep growth and production performance | |
| CN100523170C (en) | Combination fermentation process of clostridiumbutyricum and lactobacillus acidophilus | |
| CN104431352B (en) | A kind of preparation method and application of growth promotion symphysis unit bacterium solution | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN116211956B (en) | Composition for regulating intestinal tract and/or improving obesity, preparation method, chewable tablet and application thereof | |
| CN116536201B (en) | Metaplasia preparation for repairing pelvic floor muscles and preparation method and application thereof | |
| CN117551567B (en) | Metaplasia preparation for regulating endocrine and maintaining vagina and ovary as well as preparation method and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN116121130A (en) | Composite probiotics fermentation composition for improving sleep quality and application thereof | |
| CN113186118B (en) | Composite probiotic preparation for improving sow productivity and preparation method thereof | |
| CN105349467B (en) | A kind of plant extract compound probiotic timesharing fermentation culture method | |
| WO2021217693A1 (en) | Use of symbiotic fermentation product of hydrolyzed candida and japanese sake yeast | |
| CN102805341B (en) | Five-time fermentation preparation method of Chinese yam, radix astragali and salviae miltiorrhizae capsule | |
| CN114317354A (en) | Bifidobacterium animalis, culture method thereof and application thereof in promoting growth and maturation of osteocyte | |
| CN109984249A (en) | A kind of fermentation immunopotentiator and its preparation method and application | |
| CN117327631B (en) | Lactobacillus plantarum strain 10A-2 for improving anxiety and depression and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |